25,729 articles
Danny O. Jacobs
Danny O. Jacobs is an American surgeon who served as the fifth president of Oregon Health & Science University from 2018, and OHSU's first Black president.
Danon disease
Danon disease (MIM 300257), LAMP2 deficiency, glycogen storage disease IIb: rare X-linked dominant cardiomyopathy-myopathy-intellectual disability disorder from LAMP-2 protein loss, earlier and more severe in males.
Danoprevir
Danoprevir (ITMN-191, R7227, RG7227) is an oral macrocyclic HCV NS3/4A protease inhibitor approved in China in 2018; ritonavir-boosted danoprevir with interferon and ribavirin reached 97.1% SVR12 in Chinese genotype 1 patients.
Danta Vartti
Danta Vartti, a classical Ayurvedic varti (medicated stick) eye formulation from Ashtanga Hridaya Uttarasthana 11:33-33½, entry 13:5 in the Ayurvedic Formulary of India, made from animal tooth and tusk ingredients.
Danthron
Danthron (dantron, chrysazin, 1,8-dihydroxyanthraquinone, CAS 117-10-2) is an anthraquinone formerly used as a laxative, withdrawn in the US in 1999 and classified as a carcinogen by NTP and IARC.
Danti haritaki
Danti haritaki (Dantī harītakī) is an Ayurvedic semisolid leha of Terminalia chebula fruit with Baliospermum (danti) and Operculina turpethum roots, AFI formulation AFI000073, dosed 12–24 g, indicated for śopha, grahaṇī, gulma, arocaka, ānāha, and splenic disease.
Dantodbhedagadantaka rasa
Dantodbhedagadantaka rasa (दन्तोद्भेदगादान्तक ऱस), an Ayurvedic Formulary of India herbomineral tablet for teething disorders in children; 22 ingredients including four bhasmas; standardized in a 2026 JAIMS study.
Dantrolene
Dantrolene (dantrolene sodium) is a skeletal muscle relaxant and ryanodine receptor antagonist, the only specific drug for malignant hyperthermia; synthesized 1967, US-approved 1979, also used for spasticity and neuroleptic malignant syndrome.
Dapa-CKD trial
DAPA-CKD (Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease), NCT03036150: AstraZeneca-funded phase 3 trial of dapagliflozin 10 mg vs placebo in 4304 patients with proteinuric CKD stages 2–4, with or without type 2 diabetes; 39% relative risk reduction in the primary renal-cardiovascular composite endpoint.
DAPA-HF trial
DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), NCT03036124: phase 3 trial of 4,744 patients showing dapagliflozin 10 mg daily reduced worsening heart failure or cardiovascular death (HR 0.74) in HFrEF with or without diabetes.
Dapaconazole
Dapaconazole, sold as Zilt, is an imidazole antifungal developed by Brazil's Biolab as a 2% topical cream for dermatophyte infections, reaching Phase 3 trials and performing non-inferior to ketoconazole and miconazole.
Dapagliflozin
Dapagliflozin, sold as Farxiga and Forxiga, is an SGLT2 inhibitor drug for type 2 diabetes, heart failure, and chronic kidney disease, first approved in 2014.
Dapivirine
Dapivirine (DPV-VR, dapivirine vaginal ring 25 mg): an NNRTI antiretroviral delivered by a monthly silicone vaginal ring for HIV prevention in women; EMA Article 58 opinion 2020, WHO prequalified and recommended 2021, ~27–31% efficacy in phase 3 trials.
Dapoxetine
Dapoxetine (Priligy) is a short-acting SSRI taken 1-3 hours before sex for premature ejaculation; approved in Europe and elsewhere but not the USA, with 2.5-3.0-fold IELT increases in phase 3 trials.
Daprodustat
Daprodustat (Jesduvroq, GSK1278863) is an oral HIF prolyl hydroxylase inhibitor approved in 2023 by the FDA for anemia of chronic kidney disease in adults on dialysis, with a boxed thrombotic-event warning.
Dapsone
Dapsone (DDS, 4,4'-diaminodiphenylsulfone) is a sulfone antibiotic and anti-inflammatory drug, first-line with rifampicin and clofazimine in WHO leprosy multidrug therapy and used topically for acne.
DAPT score
The DAPT score is a clinical tool that predicts whether extending dual antiplatelet therapy after coronary stenting will help or harm, introduced by Robert W. Yeh in 2016.
DARA_T_ALL trial
DARA_T_ALL (NCT07021677) is a phase 2 single-arm Tata Memorial Centre trial testing daratumumab, an anti-CD38 antibody, to eradicate MRD in adults with T-ALL still MRD-positive after induction; 18 patients, one Indian site, started 2023, no results posted yet.
Darapladib
Darapladib (SB-480848, CHEMBL204021) is an oral selective Lp-PLA2 inhibitor developed by GSK for atherosclerosis. Its phase 3 trials STABILITY and SOLID-TIMI 52 failed to reduce cardiovascular events despite about 65% enzyme inhibition.
Daratumumab
Daratumumab (Darzalex, Darzalex Faspro) is a CD38-targeting human IgG1κ monoclonal antibody for multiple myeloma and AL amyloidosis, FDA-approved since November 2015, improving survival in newly diagnosed and relapsed disease.
Daratumumab regimen
A daratumumab regimen is a multiple myeloma treatment combining the CD38 antibody daratumumab with backbone drugs such as dexamethasone, bortezomib, or lenalidomide, across newly diagnosed and relapsed disease.
Daraxonrasib
Daraxonrasib, marketed as Rasonque and developed as RMC-6236, is an oral pan-RAS inhibitor from Revolution Medicines, approved by the FDA in August 2026 for metastatic pancreatic adenocarcinoma after prior therapy.
Darbepoetin alfa
Darbepoetin alfa (Aranesp) is a long-acting erythropoiesis-stimulating agent for anemia of chronic kidney disease and cancer chemotherapy, FDA approved 2001, with a 3-fold longer half-life than epoetin alfa.
Darexaban
Darexaban (YM150, darexaban maleate) is an oral direct factor Xa inhibitor developed by Astellas Pharma for VTE prophylaxis, atrial fibrillation, and acute coronary syndrome; its active glucuronide metabolite YM-222714 carries its anticoagulant effect, and development was discontinued in September 2011.
Daridorexant
Daridorexant (Quviviq), dual orexin receptor antagonist (OX1R/OX2R) insomnia drug by Idorsia, approved 2022 in US and EU; 25–50 mg nightly, ~8 h half-life, CYP3A4-metabolized.
Darier disease
Darier disease (Darier-White disease, keratosis follicularis) is a rare autosomal dominant genodermatosis caused by ATP2A2/SERCA2 mutations, producing keratotic papules, nail changes, and neuropsychiatric features, treated symptomatically with retinoids.
Darifenacin
Darifenacin is a selective muscarinic receptor antagonist, sold as Emselex in Europe and Enablex in the United States, and is used to treat symptoms of overactive bladder syndrome.
Dark Adaptation
Dark adaptation is the slow recovery of visual sensitivity in darkness after light bleaches rhodopsin, taking 30–40 minutes, driven by the retinoid cycle, and delayed in AMD, where rod intercept time is a clinical biomarker.
Darolutamide
Darolutamide (Nubeqa, ODM-201) is an oral androgen receptor inhibitor by Bayer for prostate cancer, approved 2019 (US) and 2020 (EU), with low brain penetration, few drug interactions, and favorable tolerability versus enzalutamide and apalutamide.
Darrell J. Irvine
Darrell J. Irvine is a bioengineer and immunologist, Professor and Vice Chair of Immunology & Microbiology at Scripps Research and an HHMI Investigator since 2008, known for engineering vaccine delivery.